Cassiopea receives FDA approval for acne treatment Winlevi

Credit: REUTERS/Jason Reed

ZURICH, Aug 27 (Reuters) - Swiss-listed drugmaker Cassiopea SKIN.S said on Thursday it won approval for its first medicine, an acne treatment called Winlevi, from the U.S. Food and Drug Administration, setting the stage for a likely capital increase to support the launch.

Prescription treatment Winlevi, also known generically as clascoterone, won approval for patients 12 years and older, Cassiopea said in a statement. It is a topical medicine aimed at inhibiting hormones, called androgens, thought to play a role in acne lesions in men and women.

(Reporting by Silke Koltrowitz and John Miller; editing by Thomas Seythal)

((; +41 41 528 3638;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.